123 related articles for article (PubMed ID: 2448499)
21. The response of poorly differentiated prostatic tumors to staining for prostate specific antigen and prostatic acid phosphatase: a comparative study.
Keillor JS; Aterman K
J Urol; 1987 May; 137(5):894-6. PubMed ID: 2437333
[TBL] [Abstract][Full Text] [Related]
22. [Immunohistochemical diagnosis of a case of metastatic prostate cancer to breast].
Gotoh A; Matsuura K; Yoshimura S; Takano Y
Nihon Hinyokika Gakkai Zasshi; 1989 Dec; 80(12):1828-31. PubMed ID: 2483185
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer-associated markers.
Chu TM
Immunol Ser; 1990; 53():339-56. PubMed ID: 1713065
[TBL] [Abstract][Full Text] [Related]
24. Unusual metastatic patterns of prostate adenocarcinoma.
Venable DD; Hastings D; Misra RP
J Urol; 1983 Nov; 130(5):980-5. PubMed ID: 6195357
[TBL] [Abstract][Full Text] [Related]
25. Characterization of ALVA-41 cells, a new human prostatic cancer cell line.
Nakhla AM; Rosner W
Steroids; 1994 Oct; 59(10):586-9. PubMed ID: 7533340
[TBL] [Abstract][Full Text] [Related]
26. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical localization of a prostatic secretory protein of 94 amino acids in normal prostatic tissue, in primary prostatic tumors and in their metastases.
Dubé JY; Pelletier G; Gagnon P; Tremblay RR
J Urol; 1987 Oct; 138(4):883-7. PubMed ID: 3309368
[TBL] [Abstract][Full Text] [Related]
28. Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
Ahmann FR; Schifman RB
J Urol; 1987 Mar; 137(3):431-4. PubMed ID: 2434667
[TBL] [Abstract][Full Text] [Related]
29. Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer.
Hamdy FC; Lawry J; Anderson JB; Parsons MA; Rees RC; Williams JL
Br J Urol; 1992 Apr; 69(4):392-6. PubMed ID: 1374678
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow prostatic specific antigen and prostatic acid phosphatase levels: are they helpful in staging prostatic cancer?
Morote J; Ruibal A; Pascual C; Palou J; de Torres JA
J Urol; 1987 May; 137(5):891-3. PubMed ID: 2437332
[TBL] [Abstract][Full Text] [Related]
31. Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy.
Goldrath DE; Messing EM
J Urol; 1989 Oct; 142(4):1082-4. PubMed ID: 2477560
[TBL] [Abstract][Full Text] [Related]
32. [The role of PSA in prostatic adenocarcinoma].
Manca GP
Minerva Med; 1990 Apr; 81(4):261-4. PubMed ID: 1692981
[TBL] [Abstract][Full Text] [Related]
33. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer.
Ercole CJ; Lange PH; Mathisen M; Chiou RK; Reddy PK; Vessella RL
J Urol; 1987 Nov; 138(5):1181-4. PubMed ID: 2444720
[TBL] [Abstract][Full Text] [Related]
34. Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma.
Stege R; Lundh B; Tribukait B; Pousette A; Carlström K; Hasenson M
J Urol; 1990 Aug; 144(2 Pt 1):299-302. PubMed ID: 1695689
[TBL] [Abstract][Full Text] [Related]
35. Prostatic cancer presenting as metastatic adenocarcinoma of sphenoid sinus.
Matsumoto I; Furusato M; Inomata I; Wada T; Aizawa S
Acta Pathol Jpn; 1986 Nov; 36(11):1753-6. PubMed ID: 3811915
[TBL] [Abstract][Full Text] [Related]
36. Breast metastases of prostatic carcinoma: immunohistochemical case study.
Fukutani K; Kawabe K; Matsuki K; Endo H; Mikata N; Yokoyama M
Urol Int; 1987; 42(5):395-7. PubMed ID: 2448938
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.
Sadasivan R; Morgan R; Jennings S; Austenfeld M; Van Veldhuizen P; Stephens R; Noble M
J Urol; 1993 Jul; 150(1):126-31. PubMed ID: 7685420
[TBL] [Abstract][Full Text] [Related]
38. Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry.
Vernon SE; Williams WD
J Urol; 1983 Jul; 130(1):95-8. PubMed ID: 6191050
[TBL] [Abstract][Full Text] [Related]
39. Ras oncogene and the acquisition of metastasizing properties by rectal adenocarcinoma.
Michelassi F; Erroi F; Roncella M; Block GE
Dis Colon Rectum; 1989 Aug; 32(8):665-8. PubMed ID: 2666052
[TBL] [Abstract][Full Text] [Related]
40. [Immunoperoxidase localization of prostatic acid phosphatase, prostate-specific antigen and gamma seminoprotein in primary and metastatic prostatic carcinoma].
Yamaguchi K; Sumiya H; Fuse H; Ito H; Shimazaki J; Matsuzaki O
Nihon Hinyokika Gakkai Zasshi; 1986 May; 77(5):786-90. PubMed ID: 2427766
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
